See more : Jiangsu Shemar Electric Co.,Ltd (603530.SS) Income Statement Analysis – Financial Results
Complete financial analysis of BioVaxys Technology Corp. (BVAXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioVaxys Technology Corp., a leading company in the Biotechnology industry within the Healthcare sector.
- Propanc Biopharma, Inc. (PPCB) Income Statement Analysis – Financial Results
- Global Boatworks Holdings, Inc. (GBBT) Income Statement Analysis – Financial Results
- Kura Sushi Asia Co., Ltd. (2754.TWO) Income Statement Analysis – Financial Results
- Unity Biotechnology, Inc. (UBX) Income Statement Analysis – Financial Results
- Social Capital Suvretta Holdings Corp. IV (DNAD) Income Statement Analysis – Financial Results
BioVaxys Technology Corp. (BVAXF)
About BioVaxys Technology Corp.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 133.73K | 962.71K | 726.06K | 238.77K | 0.00 |
| General & Administrative | 2.11M | 2.94M | 4.00M | 775.10K | 229.91K |
| Selling & Marketing | 156.88K | 174.30K | 1.72M | 84.51K | 0.00 |
| SG&A | 2.27M | 3.12M | 5.72M | 859.61K | 229.91K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Cost & Expenses | 2.40M | 4.08M | 6.44M | 1.10M | 229.91K |
| Interest Income | 24.85K | 15.77K | 7.66K | 137.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.40M | 3.80M | 5.98M | 1.01M | 183.34K |
| EBITDA | 0.00 | 3.58M | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.40M | 3.58M | -6.42M | -1.09M | -229.70K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.28M | -7.92M | -478.68K | -93.55K | -33.54K |
| Income Before Tax | -7.69M | -11.73M | -6.46M | -1.10M | -230.12K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 7.64M | 9.93K | 71.69K | 29.66 |
| Net Income | -7.69M | -11.73M | -6.46M | -1.17M | -230.12K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| EPS Diluted | -0.06 | -0.12 | -0.08 | -0.04 | -0.02 |
| Weighted Avg Shares Out | 134.15M | 98.18M | 82.93M | 30.05M | 11.02M |
| Weighted Avg Shares Out (Dil) | 134.14M | 98.18M | 82.93M | 28.21M | 10.39M |
BIOVAXYS PARTNER SPAYVAC FOR WILDLIFE, INC., SCALES-UP VACCINE PRODUCTION CAPACITY
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium
BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems
BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024
BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor
BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024
BioVaxys to Present at the Life Sciences Investor Forum on September 19th
BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit
BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases
SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN
Source: https://incomestatements.info
Category: Stock Reports